

CURRENT AS OF* 9/29/2023

Conference Cochairs:

Frances R. Balkwill, Barts Cancer Institute, Queen Mary University of London, London, England
Benjamin G. Neel, NYU Langone Health Perlmutter Cancer Center, New York, NY
Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL
Elizabeth M. Swisher, University of Washington, Seattle, WA

THURSDAY, OCTOBER 5

Registration and Poster set-up

3:00 pm- 5:00 pm | Harbor Ballroom Foyer

Welcome and Introduction

Frances R. Balkwill, Kunle Odunsi, Elizabeth M. Swisher
5:00 p.m. – 5:10 p.m. | Harbor Ballroom
Not CME-eligible

Opening Keynote Address

5:10 pm-6:00 pm | Harbor Ballroom

5:10-5:15

Introduction of keynote speaker

Benjamin G. Neel, NYU Langone Health Perlmutter Cancer Center, New York, NY
Not CME-eligible

5:15-6:00

Placing our bets to make a difference

David D.L. Bowtell, Peter MacCallum Cancer Center, Victoria, Australia
CME-eligible

Exploring the Role and Impact of Patients: A Collaborative Approach to Cancer Research

6:00 p.m. 7:00 p.m. | Harbor Ballroom

Session Chair: Kunle Odunsi and Elizabeth Swisher

Not CME eligible

6:00-6:05


Welcome and Introduction

Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, IL

6:05-6:15

Patient advocacy: research, policy and community outreach

Marcie Paul, Michigan Ovarian Cancer Alliance, West Bloomfield, MI



- 6:15-6:25 **A continuum of advocate involvement in research: from perfunctory to published**
Kathleen Gavin, Minnesota Ovarian Cancer Alliance, Minneapolis, MN
- 6:25-6:35 **From patient to patient advocate**
Kathleen Maxian, Ovarian Cancer Project, Buffalo, NY
- 6:35-6:40 **Future Perspectives**
Marcie Paul, Michigan Ovarian Cancer Alliance, West Bloomfield, MI
Kathleen Maxian, Ovarian Cancer Project, Buffalo, NY
Kathleen Gavin, Minnesota Ovarian Cancer Alliance, Minneapolis, MN
- 6:40-7:00 Discussion with Q&A

Lightning Talks I

7:00 p.m.-7:30 p.m. | Harbor Ballroom

Session Chair: Elizabeth Swisher

CME-eligible

Anna Salvioni, University Cancer Institute of Toulouse, Toulouse, France [A076]

James W. Webber, Brigham and Women's Hospital, Boston, MA [A045]

Yi Wen Kong, David. H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA [A035]

Emily S. Winn-Deen, Mercy BioAnalytics Inc., Natick, MA [A040]

Joanna Burdette, University of Illinois, Chicago, IL [A047]

Quentin Chartreux, Cedars-Sinai Medical Center, Los Angeles, CA [A049]

Connor Sweetnam, Syapse, Inc, San Francisco, CA [A069]

Rebecca L. Porter, Dana-Farber Cancer Institute, Boston, MA [A061]

Sergio Marchini, Humanitas Research Hospital, Rozzano, Italy [A062]

Opening Reception + Poster Session A

7:30 p.m. – 10:00 p.m. | Galleria

FRIDAY, OCTOBER 6


Continental Breakfast

7:00 am-8:00 am | Harbor Ballroom Foyer

Plenary Session 1: Tumor microenvironment and immune oncology I

8:00 am-9:30 am | Harbor Ballroom

Session Chair: Frances Balkwill (Barts Cancer Institute)



CME-eligible

- 8:00-8:30 **Fallopian tube precursors make tumors nervous**
Ronny I. Drapkin, University of Pennsylvania, Philadelphia, PA
- 8:30-9:00 **Regional combating of immunosuppressive forces in the ovarian tumor microenvironment**
Daniel J. Powell Jr., University of Pennsylvania, Philadelphia, PA
- 9:00-9:30 **Friend or foe: Reevaluating the therapeutic potential of monocytes and tumor-associated macrophages in ovarian cancer**
Oladapo O. Yeku, Massachusetts General Hospital, Boston, MA

Break

9:30 am-9:50 am | Harbor Ballroom Foyer


Spotlight on Proffered Abstracts I

9:50 am-10:50 am | Harbor Ballroom

Session Chair: Benjamin G. Neel (NYU Langone)

CME-eligible

- 9:50-10:00 **Stable subclones and acquired genomic events present after treatment of HGSC**
Jaana Oikkonen, University of Helsinki, Helsinki, Finland
- 10:00-10:10 **Activation of the integrated stress response by NXP800, an orally available, clinical-stage, investigational agent in ARID1A-mutated, platinum resistant ovarian cancer**
Paul Workman, The Institute of Cancer Research, London, United Kingdom
- 10:10-10:20 **Half of CCNE1-amplified high-grade serous ovarian carcinomas are homologous recombination deficient and platinum-sensitive**
Liisa Kauppi, University of Helsinki, Helsinki, Finland
- 10:20-10:30 **The evolution of ovarian high grade serous carcinoma from STIC lesions**
Zhao Cheng, Ovarian Cancer Action Research Centre, Imperial College London, London, United Kingdom
- 10:30-10:40 **ZNFX1 is a Master Regulator for Epigenetic Reprogramming of Mitochondrial Inflammasome Signaling and Pathogen Mimicry in Cancer Cells**
Lora Stojanovic, University of Maryland, Baltimore, MD



10:40-10:50

A novel bispecific NK cell engager targeting FSHR and Siglec-7 displays potent anti-tumor immunity against ovarian cancer

Devivasha Bordoloi, The Wistar Institute, Philadelphia, PA

Plenary Session 2: Rare ovarian tumors

11:00 p.m. – 12:30 p.m. | Harbor Ballroom

Session Chair: Kunle Odunsi (University of Chicago)

CME-eligible

11:00 -11:30

Tumor heterogeneity of ovarian clear cell carcinoma

Ruby Yun-Ju Huang, National Taiwan University, Teipei, Taiwan

11:30-12:00

Rare ovarian cancers: The sequelae of specific interactions between cell contexts mutations and microenvironments

David G. Huntsman, University of British Columbia, Vancouver, BC, Canada

12:00-12:30

Epigenetic approaches for endometriosis-associated ovarian cancer

Rugang Zhang, MD Anderson Cancer Center, Houston, TX

Lunch on own

12:30 p.m.-2:00 p.m.

Plenary Session 3: Drug discovery, development, and novel pathways

2:00 p.m. – 4:00 p.m. | Harbor Ballroom

Session Chair: Elizabeth M. Swisher (University of Washington)

CME-eligible

2:00-2:30

Latest developments in targeting the DNA damage response in the clinic

Timothy A. Yap, MD Anderson Cancer Center, Houston, TX

2:30-3:00


Advancing novel therapeutics through reverse translation

Sarah F. Adams, University of New Mexico, Albuquerque, NM

3:00-3:30

Targeting AXL in platinum-resistant ovarian cancer: From the lab bench to Phase 3 trial

Katherine C. Fuh, University of California San Francisco, San Francisco, CA



3:30-4:00

Cell cycle checkpoint pathways as therapeutic target

Jung-min Lee, National Cancer Institute, Bethesda, MD

Break

4:00 p.m. – 4:30 p.m. | Harbor Ballroom Foyer

Plenary Session 4: Early detection and prevention

4:30 p.m. – 6:30 p.m. | Harbor Ballroom

Session Chair: Kunle Odunsi (University of Chicago)

CME-eligible

4:30-5:00

Improving targeted precision prevention in ovarian cancer

Ranjit Manchanda, Barts Cancer Institute, Queen Mary University of London, London, England

5:00-5:30

Is salpingectomy as effective as bilateral salpingo-oophorectomy in preventing ovarian, fallopian tube, and peritoneal cancer? Let's prove it!

Kathryn P. Pennington, University of Washington, Seattle, WA

5:30-6:00

Opportunistic salpingectomy for ovarian cancer prevention

Gillian Hanley, University of British Columbia, Vancouver, BC, Canada

6:00-6:30

A liquid biopsy fingerprint of disease via nanoengineering

Daniel A. Heller, Memorial Sloan Kettering Cancer Center, New York, NY

Lightning Talks II

6:30 p.m.-7:00 p.m. | Harbor Ballroom

Session Chair: Frances Balkwill (Barts Cancer Institute)

CME-eligible

Dawn Cochrane, British Columbia Cancer Research Centre, BC, Canada [B054]

Veena K. Vuttaradhi, The University of Texas MD Anderson Cancer Center, Houston, TX [B057]

Fernando Perez-Villatoro, University of Helsinki, Helsinki, Finland [B073]

Hao Nie, The University of Texas MD Anderson Cancer Center, Houston, TX [B076]

Ada Junquera, University of Helsinki, Helsinki, Finland [B060]


Chi Lam Au Yeung, The University of Texas MD Anderson Cancer Center, Houston, TX [B067]

Leonard G. Frisbie, University of Pittsburgh, Pittsburgh, PA [B085]

Courtney A. Bailey, University of Colorado, Boulder, CO [B069]

Nan Zhang, The Wistar Institute, Philadelphia, PA [B086]

Wade Barton, The University of Alabama, Birmingham, Alabama [B058]



Reception + Poster Session B

7:00 p.m. – 9:30 p.m. | Galleria

SATURDAY, OCTOBER 7

Continental Breakfast

7:00 am-8:00 am | Harbor Ballroom Foyer

Plenary Session 5: Epigenetics and epitranscriptomics

8:00 am-9:30 am | Harbor Ballroom

Session Chair: Benjamin G. Neel (NYU Langone)

CME-eligible

- | | |
|-----------|---|
| 8:00-8:30 | Epigenome targeting in ovarian Cancer: preclinical models to clinic
Daniela E. Matei, Northwestern University, Chicago, IL |
| 8:30-9:00 | Gene Regulation Rewiring During High-Grade Serous Ovarian Cancer Development
Kate Lawrenson, Cedars-Sinai Medical Center, Los Angeles, CA |
| 9:00-9:30 | Targeting transposable elements with epigenetic modulators to reverse ovarian cancer immune evasion
Katherine B. Chiappanelli, The George Washington University School of Medicine and Health Sciences, Washington D.C. |


Break

9:30 am -9:45 am | Harbor Ballroom Foyer

Closing Keynote Address

9:45 am – 10:30 a.m. | Harbor Ballroom

- | | |
|------------|---|
| 9:45-9:47 | Introduction of keynote speaker
Frances R. Balkwill, Barts Cancer Institute, Queen Mary University of London, London, England
<i>Not CME-eligible</i> |
| 9:47-10:30 | Mouse models of high-grade serous carcinoma as platforms for testing prevention strategies
Kathleen R. Cho, University of Michigan Medical School, Ann Arbor, MI
<i>CME-eligible</i> |



Spotlight on Proffered Abstracts II

10:30 a.m. – 11:30 a.m. | Harbor Ballroom

Session Chair: Frances Balkwill (Barts Cancer Institute)

CME-eligible

- | | |
|-------------|--|
| 10:30-10:40 | Follicular fluid aids in cell adhesion, spreading and shows an age-dependent effect on DNA damage in fallopian tube epithelial cells
Amrita Salvi, University of Illinois, Chicago, IL |
| 10:40-10:50 | Reconstructing the metastatic tumor microenvironment of high grade serous ovarian cancer using human multicellular in-vitro models
Beatrice Malacrida, Queen Mary University of London, London, United Kingdom |
| 10:50-11:00 | Dual targeting of IDO1/TDO2 inhibits tumor progression and attenuates the immune suppressive tumor microenvironment
Benjamin G. Bitler, University of Colorado, Boulder, CO |
| 11:00-11:10 | Role of cancer associated fibroblasts in ovarian cancer relapse
Argha Ghosh, Indiana University School of Medicine, Bloomington, IN |
| 11:10-11:20 | Patient-derived immunocompetent cultures reveal personalized immunotherapies and new treatment options for therapy resistant patients with high-grade serous ovarian cancer
Anniina Färkkilä, University of Helsinki, Helsinki, Finland |
| 11:20-11:30 | Proteogenomic analysis of enriched tumor epithelium identifies prognostic signatures and an increased dependency of homologous recombination proficient cells on bmi1 in high grade serous ovarian cancer
Thomas P. Conrads, Inova Health System, Falls Church, VA |

Break


11:30 p.m.-11:45 p.m. | Harbor Ballroom Foyer

Plenary Session 6: Tumor microenvironment and immune oncology II

11:45 p.m. – 1:15 p.m. | Harbor Ballroom

Session Chair: Kunle Odunsi (University of Chicago)

CME-eligible



- 11:45-12:15 **B cells: the immune system's secret weapon against ovarian cancer**
Brad Nelson, University of British Columbia, Vancouver, BC, Canada
- 12:15-12:45 **Spatial multiomics allows identifying the genomic and proteomic changes from borderline to low-grade serous cancer**
Ernst R. Lengyel, University of Chicago, Chicago, IL
- 12:45-1:15 **Mutational processes as determinants of immune evasion in ovarian cancer**
Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, NY

Closing Remarks + Departure

- 1:15 pm Benjamin G. Neel, NYU Langone Health Perlmutter Cancer Center, New York, NY